Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2- (dipropylamino)tetralin: Synthesis and interactions with 5-HT(1A) receptors

Journal of Medicinal Chemistry

Volumn 39, Issue 20, 1996, Pages 4036-4043

  Höök, Berit Backlund ^a   Cortizo, Lourdes ^a   Johansson, Anette M ^a   Westlind Danielsson, Anita ^b   Mohell, Nina ^b   Hacksell, Uli ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b R and D Laboratories   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5 FLUORO 8 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CYCLIC AMP; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT; RECEPTOR AFFINITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CYCLIC AMP; MOLECULAR STRUCTURE; RATS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0029817838     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960329o     Document Type: Article

References (74)

1. Lecrubier, Y. Antidepressant drugs: Similar but different? In New Pharmacological Approaches to the Therapy of Depressive Disorders. Int Acad Biomed Drugs Res; Mendlewics, J., Brunello, N., Langer, S. Z., Racagni, G., Eds.; Karger: Basel, 1993; Vol. 5, pp 83-91.
2. (a) Artigas, F. 5-HT and antidepressants:new views from microdialysis studies. Trends Pharmacol Sci. 1993, 14, 262.
3. (b) Deakin, J. F. W.; Graeff, F. G.; Guimaraes, F. S. Clinical implication of microdialysis findings. Trends Pharmacol. Sci. 1993, 14, 263.
4. 1Aautoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 1993,60, 776-779.
5. (d) Blier, P.; de Montigny, C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994,15, 220-226.
6. 1Aautoreceptors in the action of selective serotonin reuptake inhibitors. Eur. J. Pharmacol. 1994, 260, 251-255.
7. 1A-receptor antagonists increase the activity of serotoninergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 352, 157-165.
8. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol. 1996,353, 630-640.
9. (a) Middlemiss, D. N.; Neill, J.; Tricklebank, M. D. Subtypes of the 5-HT receptor involved in hypothermia and forepaw treading by 8-OH-DPAT. Br. J. Pharmacol. 1985, 85, 251P.
10. 1A receptor activation in humans. Eur. J. Clin. Pharmacol. 1990, 39, 17-19.
11. (c) Bosker, F. J.; Donker, M. G.; Klompmakers, A. A.; Kurata, K.; Westenberg, H. G. M. 5-Hydroxytryptamine release in dorsal hippocampus of freely moving rats: modulation by pindolol. Prog. NeuroPsychopharmacol. Biol. Psychiatry 1994, 18, 765-778.
12. Hyttel, J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1995, 9 (Suppl. 1), 19-26.
13. Artigas, F.; Perez, V.; Alvarez, E. Pindolol induces a rapid improvment of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994, 51, 248-251.
14. 1A-Receptor Modulators. Annu. Rep. Med. Chem. 1995, 30, 1-9.
15. (b) Romero, A. G.; McCall, R. B. Advances in central serotoninergics. Annu. Rep. Med. Chem. 1992, 27, 21-30.
16. IA receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 1993, 14, 441-448.
17. 1A-receptor antagonist. J. Med. Chem. 1990,33, 1741-1544.
18. (b) Björk, L.; Lindgren, S.; Hacksell, U.; Lewander, T. (S)-UH-301 antagonizes (R)-8-OH DPAT-induced cardiovascular effects in the rat. Eur. J. Pharmacol. 1991, 199, 367-370.
19. (c) Björk, L.; Cornfield, L. J.; Nelson, D. L.; Hillver, S.-E.; Andén, N.-E.; Lewander, T.; Hacksell, U. Pharmacology of the novel 5-HT1A-receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin, (S)-UH-301: Inhibition of (R)-8-OH DPAT-induced effects. J. Pharmacol Exp. Ther. 1991, 258, 58-65.
20. 1A receptor antagonist (S)-UH-301 antagonizes 8-OH-DPAT-induced effects on male as well as female rat copulatory behaviour. Eur. J. Pharmacol. 1991,202, 81-87.
21. (e) Björk, L.; Fredriksson, A.; Hacksell, U.; Lewander, T. Effects of (R)-8-OH DPAT and the enantiomers of UH-301 on motor activities in the rat. Antagonism of (R)-8-OH DPAT-induced effects. Eur. Neuropsychopharmacol. 1992,2, 141-147.
22. 1A receptor antagonist (S)-UH-301 prevents (R)-8-OH-DPAT-induced decrease in interstitial concentrations of serotonin in the rat hippocampus. Eur. J. Pharmacol. 1992,216, 373-378.
23. 1A receptor Antagonist (S)-UH-301 in Rodents and monkeys. Brain Res. Bull. 1992,29,901-904.
24. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 347, 353-362.
25. 1A receptor antagonist (S)-UH-301 blocks the (R)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat. J. Neural Transm. Gen. Sect. 1994, 96, 179-186.
26. 1A receptor antagonist, enhances plasma corticosterone levels in the rat. Life Sci. 1994, 55, PL99-103.
27. 1A receptor. Eur. J. Pharmacol. 1995, 272, 177-183.
28. 1A-receptors. Chirality 1996, in press.
29. 1A receptors. J. Med. Chem. 1993, 36, 1509-1510.
30. 1A receptors. Ear. J. Pharmacol. 1993, 237, 283-291.
31. 1A receptor ligands (+)-WAY100135 and SDZ16-525. Eur. J. Pharmacol. 1993,249,25-35.
32. 1A receptors in vivo. Eur. J. Pharmacol. 1993, 240, 307-310.
33. (e) Hartley, J.; Fletcher, A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur. J. Pharmacol. 1994,252, 329-332.
34. 1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 1994, 267, 321-325.
35. 1A receptor antagonist. Br. J. Pharmacol. 1994, 112, 91.
36. 1A receptor antagonist WAY100635. Eur. J. Pharmacol. 1994,264, 95-97.
37. 1A receptors with positron emission tomography. Life Sci. 1994,55, 403-407.
38. 1A receptor antagonist. Brain Res. 1995, 673, 217-225.
39. 3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J. Neurochem. 1995, 64,2716-2726.
40. 1A receptors in rat brain membranes. Eur. J. Pharmacol. 1995,288, 173-186.
41. 1A receptor-related anxiolytics. Trends Pharmacol. Sci. 1987, 8, 432-437.
42. (b) New, J. S. The Discovery and Development of Buspirone: A New Approach to the Treatment of Anxiety. Med. Res. Rev. 1990, 10, 283-326.
43. 2. J. Labelled Compd. Radiopharm. 1983, 20, 1207-1211.
44. 1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure-activity relationship studies. J. Med. Chem. 1994, 37, 1779-1793.
45. McOmie, J. F. W.; West, D. E. 3.3-Dihydroxybiphenol. In Organic Syntheses; Baumgarten, H. E., Eds.; John Wiley & Sons, Inc.: New York, 1973; Collect. Vol. V, pp 412-414.
46. Kiesewetter, D. O.; Katzenellenbogen, J. A.; Kilbourn, M. R.; Welch, M. J. Synthesis of 16-Fluoroestrogens by Unusually Facile Fluoride Ion Displacement Reactions: Prospects for the Preparation of Fluorine-18 Labeled Estrogens. J. Med. Chem. 1984, 49, 4900-4905.
47. Cabri, W.; Candiani, I.; Bedeschi, A. Ligand-Controlled a-Regioselectivity in Palladium-Catalyzed Arylation of Butyl VinyI Ether. J. Org. Chem. 1990, 55, 3654-3655.
48. Echavarren, A. M.; Stille, J. K. Palladium-Catalyzed Carbonylative Coupling of Aryl Triflates with Organostannanes. J. Am. Chem. Soc. 1988, 110, 1557-1565.
49. (a) Pinhey, J. T.; Roche, E. G. The Chemistry of Organolead(IV) Tricarboxylates. Synthesis and Electrophilic Heteroarylation Reactions of 2- and 3-Thienyl-, and 2- and 3-Furyl-lead Tricarboxylates. J. Chem. Soc., Perkin Trans. 1 1988, 2415-2421.
50. (b) Echavarren, A. M.; Stille, J. K. Palladium-Catalyzed Coupling of Aryl Triflates with Organostannanes. J. Am. Chem. Soc. 1987, 109, 5478-5486.
51. (a) Roques, B. P.; Florentin, D.; Callanquin, M. The Study of a and b Furanboronic Acids. J. Heterocycl. Chem. 1975,12, 195-196.
52. (b) Huth, A.; Beetz, I.; Schumann, I. Synthesis of Diarylic Compounds by Palladium Catalyzed Reaction of Aromatic Triflates with Boronic Acids. Tetrahedron 1989, 45, 6679-6682.
53. Cacchi, S.; Ciattini, P. G.; Morera, E.; Ortar, G. Palladium-Catalyzed Triethylammonium Formate Reduction of Aryl Triflates. A Selective Method for the Deoxygenation of Phenols. Tetrahedron Lett. 1986, 27, 5541-5544.
54. 1A Receptors. J. Med. Chem. 1993, 36, 4221-4229.
55. 2-Receptor Antagonists. J. Med. Chem. 1995, 38, 150-160.
56. i < 0.3 nM) could not be determined under the experimental conditions used.
57. i < 0.3 nM) could not be determined under the experimental conditions used.
58. For example: (S)-8-acetyl-2-(dipropylamino)tetralin and (S)-methyl 2-(dipropylamino)tetralin-8-carboxylate (ref 19a), (1R,2S)-8-furyl-1-methyl-2-(dipropylamino)tetralin (ref 19b), (S)-8-(2-furyl)-2-(dipropylamino)tetralin (ref 22a), and (S)-8-hydroxy-2-(dibutylamino)tetralin (ref 22b).
59. 1A-receptors. Eur. J. Med. Chem. 1995, 30, 277-286.
60. 1A receptors in the brain. J. Med. Chem. 1989, 32, 779-783.
61. 1A Receptors in the Brain. J. Med. Chem. 1989, 32, 2311-2318.
62. 1A receptors in the brain. Eur. J. Med. Chem. 1991, 26, 215-220.
63. (e) Stjärnlöf, P.; Gullme, M.; Elebring, T.; Andersson, B.; Wikström, H.; Lagerkvist, S.; Ekman, A.; Carlsson, A.; Sundell, S. (S)- and (R)-Di-n-propylamino-6,7,8,9-tetrahydro-3H-benzo[e]indole-1-carbaldehyde. J. Med. Chem. 1993, 36, 2059-2065.
64. 1A receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus. Br. J. Pharmacol. 1992, 107, 141-145.
65. Fargin, A.; Raymond, J. R.; Regan, J. W.; Cotecchia, S.; Lefkowitz, R, J.; Caron, M. G. Effector coupling mechanism of the cloned 5-HT1A receptor. J. Biol. Chem. 1989, 264, 14848-14852.
66. (a) Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H. 8-Hydroxy-2-(di-n-propylamino)tetralin, a New Centrally Acting 5-Hydroxytryptamine Receptor Agonist. J. Med. Chem. 1981, 24, 921-923.
67. (b) Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G. 8-Hydroxy-2-(Di-n-Propylamino)Tetralin, 8-OH-DPAT, a Potent and Selective Simplified Ergot Congener with Central 5-HT-Receptor Stimulating Activity. J. Neural Transm. 1982,55, 169-188.
68. 1, Recognition Site. Eur. J. Pharmacol. 1983,90, 151-153.
69. 3H-PAT. Nature 1983, 305, 140-142.
70. Roques, B. P.; Florentin, D.; Callanquin, M. J. Heterocycl. Chem. 1975, 12, 195-196.
71. Dorflinger, L. J.; Schonbrunn, A. Somatostatin inhibits vasoactive intestinal peptide-stimulated cyclic adenosine monophosphate accumulation i GH pituitary cells. Endocrinology 1983, 113, 1541-1550.
72. Brown, B. L.; Ekins, R. P.; Albano, J. D. M. Saturation Assay for Cyclic AMP Using Endogenous Binding Protein. Adv. Cyclic Nucleotide Res. 1972, 2, 25-40.
73. Nordstedt, C.; Fredholm, B. B. A Modification of a Protein-Binding Method for Rapid Quantification of cAmp in Cell-Culture Supernatants and Body Fluid. Anal. Biochem. 1990, 189, 231-234.
74. 1A Serotonin Ligands. J. Med. Chem. 1988, 31, 1968-1971.